Olaratumab
- Generic Name
- Olaratumab
- Brand Names
- Lartruvo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1024603-93-7
- Unique Ingredient Identifier
- TT6HN20MVF
- Background
Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the treatment of olaratum...
- Indication
用于治疗软组织肉瘤。
- Associated Conditions
- Soft Tissue Sarcoma
- Associated Therapies
- -
A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 49
- Registration Number
- NCT02326025
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Washington University Medical Center, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath